Daily Update - Dec 12, 2022

By: Matthew Otto



The company announced the topline data from its Phase 2 REDIRECT clinical study, showing that AFM13 monotherapy could effectively treat relapsed/refractory peripheral T cell lymphoma patients. The study reported an impressive 32.4% objective response rate, a median duration of response of 2.3 months, and a progression-free survival period lasting 3.5 months on average, with an overall survival of 13.8 months for patients who had multiple prior lines of therapy, all with a differentiated safety profile. These response rates were comparable regardless of patients’ CD30 expression levels or prior brentuximab vedotin therapy. Given the observed synergy between AFM13 and AB-101 NK cells in Hodgkin lymphomas, Affimed plans to prioritize investment in the combination approach for PTCL treatment.

  • Piper Sandler’s Do Kim reduced his target price from $7 to $6 while keeping an Overweight rating.
  • Swayampakula Ramanth initiated coverage with a Buy Rating plus lowered HC Wainwright & Co.’s target from $10 to $6.
  • Daina Graybosch at SVB Leerink cut her forecast down from $10 to $6.

HCA Healthcare

Analysts on Wall Street are taking notice of HCA :

  • Goldman Sachs analyst Jamie Perse boosted his target from $233 to a lofty $265
  • Loop Capital analyst Joseph France took moved his rating from Hold to Buy with a target price set at $95.



  • Goldman Sachs analyst Brooke Roach gave Kontoor Brands a price target upgrade from $36 to $41 while maintaining aNeutral rating.


  • Kate McShane’s review on Academy Sports pushed her own price target to 65$.

Although Academy Sports’ net sales for the third quarter of 2022 were down, with a 7.2% drop in comparable store sales, the company saw significant improvements compared to the same period two years ago. E-commerce and total purchases both increased by 30.5%. Despite this positive trend, the company faced some costs, such as inventory shrinkage and higher shipping fees, which impacted the overall gross margin, decreasing it by 20 basis points compared to last year’s figure.



  • Stock received a double dose of analyst attention as Goldman Sachs and Barclays analysts Kate McShane, Adrienne Yih upgraded their price targets from Neutral to Sell, and $243 to $254 respectively. Both maintained an Equal-Weight rating on the company.


  • Dan Dolev from Mizuho has lowered the stock forecast for PayPal Holdings from a high of $118 to just $105, yet still maintains his Buy recommendation.